|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
90,552,000 |
Market
Cap: |
3.31(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$18.07 - $44.07 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 8 |
Insider 3/6 Months : 8.6 |
|
Guru Rank Number : 538 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
7,700 |
7,700 |
7,700 |
Total Buy Value |
$0 |
$198,736 |
$198,736 |
$198,736 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
1 |
Total Shares Sold |
26,156 |
72,347 |
84,013 |
300,515 |
Total Sell Value |
$921,768 |
$2,218,045 |
$2,683,017 |
$13,658,321 |
Total People Sold |
4 |
9 |
10 |
16 |
Total Sell Transactions |
6 |
28 |
29 |
90 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Pauwels Eric |
CHIEF BUSINESS OFFICER |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
24,300 |
68,481 |
|
- |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2024-01-30 |
4 |
S |
$27.25 |
$21,637 |
D/D |
(794) |
71,189 |
|
-39% |
|
Pauwels Eric |
CHIEF BUSINESS OFFICER |
|
2024-01-30 |
4 |
S |
$27.25 |
$9,974 |
D/D |
(366) |
44,181 |
|
-39% |
|
Utter Christine Marie |
SVP, CHIEF ACCOUNTING OFFICER |
|
2024-01-30 |
4 |
S |
$27.25 |
$8,666 |
D/D |
(318) |
35,528 |
|
-39% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2024-01-30 |
4 |
S |
$27.25 |
$763 |
I/I |
(28) |
3,706 |
|
-39% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2024-01-30 |
4 |
S |
$27.25 |
$16,841 |
D/D |
(618) |
61,202 |
|
-39% |
|
Jacobson Allan Steven |
|
|
2024-01-22 |
4 |
AS |
$27.38 |
$273,804 |
D/D |
(10,000) |
12,348 |
|
33% |
|
Jacobson Allan Steven |
|
|
2024-01-22 |
4 |
OE |
$27.05 |
$270,500 |
D/D |
10,000 |
22,348 |
|
- |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2024-01-09 |
4 |
S |
$29.01 |
$2,901 |
I/I |
(100) |
3,734 |
|
-40% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2024-01-09 |
4 |
S |
$29.01 |
$44,132 |
D/D |
(1,521) |
61,820 |
|
-40% |
|
Pauwels Eric |
CHIEF BUSINESS OFFICER |
|
2024-01-09 |
4 |
S |
$29.01 |
$59,916 |
D/D |
(2,065) |
44,547 |
|
-40% |
|
Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
|
2024-01-09 |
4 |
S |
$29.01 |
$157,928 |
D/D |
(5,443) |
160,475 |
|
-40% |
|
Utter Christine Marie |
SVP, FINANCE & CAO |
|
2024-01-09 |
4 |
S |
$29.01 |
$47,961 |
D/D |
(1,653) |
35,846 |
|
-40% |
|
Golden Lee Scott |
CHIEF MEDICAL OFFICER |
|
2024-01-09 |
4 |
S |
$29.01 |
$35,543 |
D/D |
(1,225) |
37,914 |
|
-40% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2024-01-09 |
4 |
S |
$29.01 |
$56,231 |
D/D |
(1,938) |
71,983 |
|
-40% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2024-01-08 |
4 |
S |
$28.64 |
$1,518 |
I/I |
(53) |
3,834 |
|
-10% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2024-01-08 |
4 |
S |
$28.64 |
$35,399 |
D/D |
(1,236) |
63,341 |
|
-10% |
|
Schmertzler Michael |
|
|
2024-01-08 |
4 |
AS |
$27.81 |
$41,715 |
D/D |
(1,500) |
115,266 |
|
10% |
|
Pauwels Eric |
CHIEF BUSINESS OFFICER |
|
2024-01-08 |
4 |
S |
$28.64 |
$44,937 |
D/D |
(1,569) |
46,612 |
|
-10% |
|
Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
|
2024-01-08 |
4 |
S |
$28.64 |
$64,068 |
D/D |
(2,237) |
165,918 |
|
-10% |
|
Utter Christine Marie |
SVP, FINANCE & CAO |
|
2024-01-08 |
4 |
S |
$28.64 |
$34,025 |
D/D |
(1,188) |
37,499 |
|
-10% |
|
Golden Lee Scott |
CHIEF MEDICAL OFFICER |
|
2024-01-08 |
4 |
S |
$28.64 |
$22,196 |
D/D |
(775) |
39,139 |
|
-10% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2024-01-08 |
4 |
S |
$28.64 |
$41,729 |
D/D |
(1,457) |
73,921 |
|
-10% |
|
Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
|
2024-01-05 |
4 |
S |
$27.15 |
$274,393 |
D/D |
(10,107) |
168,155 |
|
-22% |
|
Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
|
2023-12-28 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
177,961 |
|
- |
|
568 Records found
|
|
Page 2 of 23 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|